Update of the guidelines for the pharmacological treatment of rheumatoid arthritis by the Mexican College of Rheumatology 2023
Carlos Abud-Mendoza,Francisco Javier Aceves-Ávila,César Alejandro Arce-Salinas,José Álvarez Nemegyei,Leonor Barile-Fabris,Sergio Durán-Barragán,Diana Elsa Flores-Alvarado,Eufrates Hernández-Núñez,Fedra Irazoque-Palazuelos,José Francisco Moctezuma-Ríos,Virginia Pascual-Ramos,Margarita Portela-Hernández,Luis Humberto Silveira,Lilia Andrade-Ortega,Ana Barrera-Vargas,Sandra Carrillo-Vázquez,Zully Castro-Colin,Enrique Cuevas-Orta,Luis Felipe Flores-Suárez,Guillermo Arturo Guaracha-Basáñez,María Fernanda Hernández-Cabrera,Iván de Jesús Hernández-Galarza,David Alejandro Herrera-vanOostdam,Adriana Concepción Lobato-Belmonte,Laura Aline Martínez-Martínez,Marco Ulises Martínez-Martínez,Gabriel Medrano-Ramírez,Francisco Javier Merayo-Chalico,Graciela Meza-López Y Olguín,Francisco Olan,Genaro Peña-Santos,César Ramos-Remus,Greta Reyes-Cordero,Vijaya Rivera-Terán,Jorge Rojas-Serrano,Griselda Serna-Peña,Sandra Sicsik-Ayala,César Armando Sifuentes-Cantú,David Vega-Morales,Pablo Villaseñor-Ovies,Daniel Xibillé-Friedmann,César Pacheco-Tena
DOI: https://doi.org/10.1016/j.reumae.2024.02.009
Abstract:Objective: To develop updated guidelines for the pharmacological management of rheumatoid arthritis (RA). Methods: A group of experts representative of different geographical regions and various medical services catering to the Mexican population with RA was formed. Questions based on Population, Intervention, Comparison, and Outcome (PICO) were developed, deemed clinically relevant. These questions were answered based on the results of a recent systematic literature review (SLR), and the evidence's validity was assessed using the GRADE system, considered a standard for these purposes. Subsequently, the expert group reached consensus on the direction and strength of recommendations through a multi-stage voting process. Results: The updated guidelines for RA treatment stratify various therapeutic options, including different classes of DMARDs (conventional, biologicals, and JAK inhibitors), as well as NSAIDs, glucocorticoids, and analgesics. By consensus, it establishes the use of these in different subpopulations of interest among RA patients and addresses aspects related to vaccination, COVID-19, surgery, pregnancy and lactation, and others. Conclusions: This update of the Mexican guidelines for the pharmacological treatment of RA provides reference points for evidence-based decision-making, recommending patient participation in joint decision-making to achieve the greatest benefit for our patients. It also establishes recommendations for managing a variety of relevant conditions affecting our patients.